Navigation Links
Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
Date:8/24/2011

PARIS and MINNEAPOLIS, Aug. 24, 2011 /PRNewswire/ -- Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in biogenetics, announced today that they have entered a development and license agreement on the creation of transgenic large livestock.

Recombinetics creates, in accordance with biosafety and animal well-being requirements, large livestock for agricultural, biomedical and bioproduction applications. Following this agreement, Recombinetics will use Cellectis bioresearch's engineered nucleases to conceive animals with improved genetic features.

The agreement, which will run for 3 years, is exclusive for swine, cattle and sheep and non-exclusive for goat. It broadens the field of applications for the genome customization tools designed and produced by Cellectis bioresearch, emphasizing the versatility of its nucleases.

"We have been amazed by the enthusiasm of the Recombinetics management team and the company's robust results in the genetic engineering of large livestock," said Marc Le Bozec, CEO of Cellectis bioresearch. "Applying our technologies in this new field of application should enable Recombinetics to accelerate its development on this promising market."

"This license enables us to apply the full potential of precision genetics to a variety of livestock applications. In agriculture we will focus on the acceleration of breeding programs by rapid allele introgression. In the biomedical space we will emphasize the addition of new characteristics to animals used in therapeutic development," said Scott Fahrenkrug, CEO of Recombinetics.

Under the terms of the agreement, Cellectis bioresearch is eligible to sales-based milestones of up to $50M and to royalties on the sales generated by the products developed during this collaboration.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The genome customization products and services can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.

Follow Cellectis bioresearch on twitter : http://twitter.com/genegineer

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

About Recombinetics

Recombinetics is a privately held company with extensive international relationships in agriculture and animal biotechnology. For further information about Recombinetics, visit at www.recombinetics.com. Follow Recombinetics on twitter: http://twitter.com/recombinetics

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
2. TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards
3. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
4. Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells
5. Cellectis Receives Payment for License to Homologous Recombination Patents
6. Cellectis Publishes 2010 Financial Results
7. Cellectis and the Etablissement Francais du Sang Launch StemRed, a Program to Produce Red Blood Cells From Stem Cells
8. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
9. Cellectis Meganuclease Technology Used to Efficiently Prevent Viral Infection
10. Cellectis bioresearch Announces the First TGCA Winner
11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere ... cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ... for its increasing popularity is due to its new team building format, a way for ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
Breaking Biology Technology:
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
Breaking Biology News(10 mins):